RAPP Rapport Therapeutics Net earnings per share for the last 12 months

Rapport Therapeutics, Inc. (RAPP) relies on the high margins of future sales of approved molecules. The trailing twelve-month earnings per share visualizes this potential, where -3.18 serves as the final level marker. While drug discovery automation via AI platforms minimizes manual labor, the risk of early-stage trial failure and a rapid cash burn are currently exerting pressure on the stock price.
Rapport Corp - analytical breakdowns and key metrics (RAPP)

For the neurobiological startup Rapport Therapeutics, Inc. (RAPP), which independently conducts clinical trials, the annual net income per share trend reflects the efficiency of capital expenditures on pipeline development without external mergers. This metric is calculated as the ratio of the final financial result over the last twelve months to the number of shares, allowing investors to assess the real return on each share and the volatility of the business's fundamental momentum.